CRISPR Therapeutics AG (NASDAQ:CRSP)

91.72
Delayed Data
As of Oct 30
 -4.63 / -4.81%
Today’s Change
32.30
Today|||52-Week Range
111.90
+50.60%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$6.6B

Company Description

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Contact Information

CRISPR Therapeutics AG
Baarerstrasse 14
Zug Zug 6300
P:(141) 561-3277
Investor Relations:

Employees

Shareholders

Mutual fund holders45.04%
Individual stakeholders29.85%
Other institutional11.99%

Top Executives

Rodger NovakChairman & President
Samarth KulkarniChief Executive Officer & Director
Lawrence O. KleinChief Operating & Business Officer
Michael John TomsicekCFO & Principal Accounting Officer
Tony W. HoExecutive VP, Head-Research & Development